1. Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial. (31st December 2023) Authors: Thyssen, Jacob P.; Werfel, Thomas; Barbarot, Sebastien; Hunter, Hamish J.A; Pierce, Evangeline; Sun, Luna; Cirri, Lisa; Buchanan, Andrew S.; Lu, Na; Wollenberg, Andreas Journal: Journal of dermatological treatment Issue: Volume 34:Number 1(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗